29.05

1.97% 0.56

After Hours: 29.06 0.010 +0.03%

Roivant Sciences Ltd (ROIV)

Overview News Price History Option Chain Financials Why ROIV Down? Discussions Forecast

Roivant Sciences Ltd stock is traded at $29.05, with a volume of 3.49M. It is up +1.97% in the last 24 hours and up +1.72% over the past month. Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Previous Close:

$28.49

Open:

$28.92

24h Volume:

3.49M

Relative Volume:

0.61

Market Cap:

$20.89B

Revenue:

$8.26M

Net Income/Loss:

$-397.91M

P/E Ratio:

-57.68

EPS:

-0.5036

Net Cash Flow:

$-758.56M

1W Performance:

+2.83%

1M Performance:

+1.72%

6M Performance:

+42.19%

1Y Performance:

+162.18%

1-Day Range:

$28.31

$29.31

1-Week Range:

$28.18

$29.64

52-Week Range:

$10.71

$32.79

Roivant Sciences Ltd Stock (ROIV) Company Profile

Name

Roivant Sciences Ltd

Sector

Healthcare (1107)

Industry

Biotechnology (616)

Phone

441-295-5950

Address

7TH FLOOR, 50 BROADWAY, LONDON

Employee

721

Twitter

Next Earnings Date

2026-05-20

Latest SEC Filings

ROIV's Discussions on Twitter

Compare ROIV vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ROIV Roivant Sciences Ltd	29.05	20.49B	8.26M	-397.91M	-758.56M	-0.5036
VRTX Vertex Pharmaceuticals Inc	445.77	112.43B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	616.18	64.09B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	884.00	54.88B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	297.69	39.01B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	149.55	31.57B	742.00K	-1.37B	-1.07B	-7.0731

Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-20-26	Initiated	Bernstein	Outperform
Sep-02-25	Initiated	Citigroup	Buy
Jul-10-25	Resumed	Goldman	Buy
Feb-15-24	Initiated	Wolfe Research	Outperform
Jan-05-24	Initiated	Piper Sandler	Overweight
Dec-12-23	Initiated	Deutsche Bank	Buy
Oct-17-23	Initiated	Guggenheim	Buy
Jun-08-23	Initiated	BofA Securities	Neutral
Oct-27-22	Initiated	JP Morgan	Overweight
May-23-22	Initiated	SVB Leerink	Outperform
Apr-29-22	Initiated	Cantor Fitzgerald	Overweight
Dec-15-21	Initiated	Goldman	Buy
Nov-08-21	Initiated	H.C. Wainwright	Buy
Oct-28-21	Initiated	Citigroup	Buy
Oct-26-21	Initiated	Cowen	Outperform
Oct-26-21	Initiated	Jefferies	Buy
Oct-26-21	Initiated	Truist	Buy

View All

Roivant Sciences Ltd Stock (ROIV) Latest News

01:46 AM

Guggenheim Remains Bullish on Roivant Sciences Ltd. (ROIV) - Insider Monkey

01:46 AM

01:09 AM

ROIV: Brepocitinib leads a robust pipeline targeting rare diseases, with strong data and launch plans - TradingView

01:09 AM

12:30 PM

ROIV: Late-stage pipeline advances in rare diseases and immunology, with strong financial flexibility - TradingView

12:30 PM

Jun 08, 2026

Roivant anticipates $950M Moderna payment in July as it outlines 2H 2026 mosliciguat and IMVT-1402 readouts - MSN

Jun 08, 2026